Brooks, T. R., Zabor, E. C., Bedelu, Y. B., Yang, X., Karimi, Y. H., Nedved, A. N., Wang, Y., Dave, N., Landsburg, D. J., Baron, K., Hu, B., Trotier, D. C., Pophali, P. A., Miller, J., Grover, N., Reinert, C., Major, A., Schwarz, T., Patel, K., Salafian, K., Ayers, E., Sundaram, S., Brody, J. D., McKenna, M., Tiger, Y. K. R., Sears-Smith, M., Ghosh, N., Peterson, C., Khan, C., Bliven, S. P., Narkhede, M., Gibson, A., Kline, J., Muñoz, J., Garza-Morales, R., Ho, C. I., Smith, S. D., Niu, A., Hernandez-Ilizaliturri, F., Chinyengetere, F., Dave, S., Abdel-Razeq, N., Moustafa, M. A., Caimi, P. F., Hill, B. T. (2025). Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab. Blood. https://doi.org/10.1182/blood.2025029117